Literature DB >> 4029243

Long-term effects of pinacidil in hypertensive dialysis patients.

E G Breen, D Mulhall, J A Keogh.   

Abstract

In an open study, thirteen chronic dialysis patients with nonvolume dependent uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks. Seven patients were taking concomitant antihypertensive therapy. Twelve patients achieved long-term blood pressure control on a mean dose of 33 mg/day. The baseline supine blood pressure was 184/116 mmHg. After 1 week it had fallen to 161/95 mmHg and blood pressure control was maintained over the study period. Patient weight remained stable. The baseline reading was 61.6 kg and at the end of the study it was 59.7 kg. Pulse rate did not change significantly. For the eight patients not taking beta-blockers the mean change in pulse rate was 7.6 beats/min supine and 6.3 beats/min erect (NS). Pretrial urea and creatinine were 27.6 mmol/l and 1027 mumol/l and after 25 weeks they were 29.6 mmol/l and 1087 mumol/l, respectively (NS). Four patients had ECG evidence of left ventricular hypertrophy before the study and one on completion of the trial. Five patients showed correction of T-waves on their ECG's. Six patients experienced side effects, none of which warranted withdrawal of treatment. These findings suggest that pinacidil is a valuable alternative treatment for hypertensive dialysis patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029243     DOI: 10.1007/bf00544353

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  The control of hypertension in patients undergoing regular maintenance hemodialysis.

Authors:  A R Hull; D L Long; R C Prati; W A Pettinger; T F Parker
Journal:  Kidney Int Suppl       Date:  1975-01       Impact factor: 10.545

2.  Angina-like syndrome with diazoxide therapy for hypertensive crisis.

Authors:  S A Kanada; D J Kanada; R A Hutchinson; D Wu
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

3.  Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction.

Authors:  A Blumberg; W B Nelp; R M Hegstrom; B H Scribner
Journal:  Lancet       Date:  1967-07-08       Impact factor: 79.321

4.  Bilateral nephrectomy for malignant hypertension.

Authors:  J F Mahony; G R Gibson; A G Sheil; B G Storey; G S Stokes; J H Stewart
Journal:  Lancet       Date:  1972-05-13       Impact factor: 79.321

5.  Vascular effects in dogs of pinacidil (P 1134), a novel vasoactive antihypertensive agent.

Authors:  U B Olsen; E Arrigoni-Martelli
Journal:  Eur J Pharmacol       Date:  1983-04-08       Impact factor: 4.432

6.  Adrenergic regulation of blood pressure in chronic renal failure.

Authors:  J J Lilley; J Golden; R A Stone
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

7.  Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.

Authors:  J E Carlsen; T Kardel; T Hilden; M Tangø; J Trap-Jensen
Journal:  Clin Physiol       Date:  1981-08

8.  Serial electrocardiographic changes during long-term treatment of severe hypertension with minoxidil.

Authors:  D Hall; K L Froer; W Rudolph
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

9.  Control of hypertension and prolonged survival on maintenance hemodialysis.

Authors:  B Charra; E Calemard; M Cuche; G Laurent
Journal:  Nephron       Date:  1983       Impact factor: 2.847

10.  Propranolol effects in long-term hemodialysis patients with renin-dependent hypertension.

Authors:  A Lindner; S W Douglas; J W Adamson
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

View more
  1 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.